ArticleBMC biotechnology2023
Effect of poly (lactic-co-glycolic acid) polymer nanoparticles loaded with vancomycin against Staphylococcus aureus biofilm.
Article in BMC biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Antibacterial and antibiofilm activities of curcumin-mediated green-synthesised silver nanoparticles against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.BMC biotechnology · 2026Article
- Enzyme therapy as a promising strategy to overcome multi-drug resistance in pathogens: current advances, key challenges, and future directions.RSC advances · 2026Review
- Formulation Development andCurrent drug delivery · 2026Article
- Nanostructured Lipid Carriers Co-Loaded with Doxycycline, Gentamicin, and Thymol for Enhanced Intracellular Antibacterial Activity AgainstInternational journal of nanomedicine · 2026Article
- The effectiveness of hydrogel matrix containing nitric oxide, silver nanoparticles, vancomycin, and ciprofloxacin on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa biofilm isolated from patients with chronic rhinosinusitis.European journal of medical research · 2025Article
- Advanced biopolymer nanocomposites for real-time biosurveillance and defense against antimicrobial resistance and viral threats.RSC advances · 2025Review
- Wound healing properties and antibiofilm activity of hydrogel matrix containing nitric oxide, silver nanoparticles, and ciprofloxacin against Pseudomonas aeruginosa burn wound infection.Scientific reports · 2025Article
- Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.Biology · 2025Review
- Antimicrobial Efficacy of Cloxacillin-Loaded Chitosan Nanoparticles Against Staphylococcus aureus Biofilms in Subclinical Mastitis.Current microbiology · 2025Article
- Antibiotic-Loaded Nano-Sized Delivery Systems: An Insight into Gentamicin and Vancomycin.Journal of functional biomaterials · 2024Review
- Antibacterial and antibiofilm potentials of vancomycin-loaded niosomal drug delivery system against methicillin-resistant Staphylococcus aureus (MRSA) infections.BMC biotechnology · 2024Article
- Co-delivery of doxycycline and rifampicin using CdTe-labeled poly (lactic-co-glycolic) acid for treatment of Brucella melitensis infection.BMC chemistry · 2024Article
- Antibacterial and antibiofilm activity of silver nanoparticles stabilized with C-phycocyanin against drug-resistantFrontiers in bioengineering and biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is a unique challenge for the healthcare system because it can form biofilms, is resistant to the host's immune system, and is resistant to numerous antimicrobial therapies. The aim of this study was to investigate the effect of poly (lactic-co-glycolic acid) (PLGA) polymer nanoparticles loaded with vancomycin and conjugated with lysostaphin (PLGA-VAN-LYS) on inhibiting S. aureus biofilm formation. Nano drug carriers were produced using the double emulsion evaporation process. we examined the physicochemical characteristics of the nanoparticles, including particle size, polydispersity index (PDI), zeta potential, drug loading (DL), entrapment efficiency (EE), Lysostaphin conjugation efficiency (LCE), and shape. The effect of the nano drug carriers on S. aureus strains was evaluated by determining the minimum inhibitory concentration (MIC), conducting biofilm formation inhibition studies, and performing agar well diffusion tests. The average size, PDI, zeta potential, DL, EE, and LCE of PLGA-VAN-LYS were 320.5 ± 35 nm, 0.270 ± 0.012, -19.5 ± 1.3 mV, 16.75 ± 2.5%, 94.62 ± 2.6%, and 37% respectively. Both the agar well diffusion and MIC tests did not show a distinction between vancomycin and the nano drug carriers after 72 h. However, the results of the biofilm analysis demonstrated that the nano drug carrier had a stronger inhibitory effect on biofilm formation compared to the free drug. The use of this technology for treating hospital infections caused by the Staphylococcus bacteria may have favorable effects on staphylococcal infections, considering the efficacy of the nano medicine carrier developed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.